| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 26, 2003
From the Division of Cardiology, Department of Pediatrics, Children’s Hospital of Wisconsin, Milwaukee (J.F.S.); Children’s Memorial Hospital, Chicago, Ill (N.L.G., B.J.D.); The Heart Institute for Children, Oak Lawn, Ill (B.F.C.); the Departments of Maternal-Fetal Medicine, Evanston Hospital, Evanston, Ill (S.N.M., B.V.P.); Christ Hospital, Oak Lawn, Ill (L.F.); Rush-Presbyterian St-Luke’s Hospital, Prentice Woman’s Hospital (M.H.), Chicago, Ill (B.V.P.); and University Medical Center, Utrecht, the Netherlands (M.M.M., M.A.O., E.J.M.). * To whom correspondence should be addressed. E-mail: jstrasbu{at}mcw.edu.
Background--Fetal tachycardia complicated by ventricular dysfunction and hydrops fetalis carries a significant risk of morbidity and mortality. Transplacental digoxin is effective therapy in a small percentage, but there is no consensus with regard to antiarrhythmic treatment if digoxin fails. This study evaluates the safety, efficacy, and outcome of amiodarone therapy for digoxin-refractory fetal tachycardia with heart failure. Methods and Results--Fetuses with incessant tachycardia and either hydrops fetalis (n=24) or ventricular dysfunction (n=2) for whom digoxin monotherapy and secondary antiarrhythmic agents (n=13) were not effective were treated transplacentally with a loading dose of oral amiodarone for 2 to 7 days, followed by daily maintenance therapy for <1 to 15 weeks. Digoxin therapy was continued throughout gestation. Newborns were studied by transesophageal pacing or ECG monitoring to determine the mechanism of tachycardia. Three fetuses were delivered urgently in tachycardia during amiodarone loading, and 3 required additional antiarrhythmic agents for sustained cardioversion. Amiodarone or amiodarone combinations converted 14 of 15 (93%) with reentrant supraventricular tachycardia, 2 of 2 with ventricular or junctional ectopic tachycardia, and 3 of 9 (33%) with atrial flutter. Amiodarone-related adverse effects were transient in 5 infants and 8 mothers. Mean gestational age at delivery was 37 weeks, with 100% survival. Conclusions--Orally administered amiodarone is safe and effective treatment for drug-refractory fetal tachycardia, specifically reentrant supraventricular tachycardia, junctional ectopic, or ventricular tachycardia, even when accompanied by hydrops fetalis or ventricular dysfunction.
Revised on October 15, 2003
Accepted on October 19, 2003
Amiodarone Therapy for Drug-Refractory Fetal Tachycardia
Janette F. Strasburger MD*,
This article has been cited by other articles:
![]() |
P. Presbitero, G. G. Boccuzzi, C. J.M. Groot, and J. W. Roos-Hesselink CHAPTER 33 Pregnancy and Heart Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A.S. Killen and F. A. Fish Fetal and Neonatal Arrhythmias NeoReviews, June 1, 2008; 9(6): e242 - e252. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-J. Trappe Acute Therapy of Maternal and Fetal Arrhythmias During Pregnancy J Intensive Care Med, September 1, 2006; 21(5): 305 - 315. [Abstract] [PDF] |
||||
![]() |
The International Liaison Committee on Resuscitati The International Liaison Committee on Resuscitation (ILCOR) Consensus on Science With Treatment Recommendations for Pediatric and Neonatal Patients: Pediatric Basic and Advanced Life Support Pediatrics, May 1, 2006; 117(5): e955 - e977. [Abstract] [Full Text] [PDF] |
||||
![]() |
Part 6: Pediatric Basic and Advanced Life Support Circulation, November 29, 2005; 112(22_suppl): III-73 - III-90. [Full Text] [PDF] |
||||
![]() |
H. R. Singh, S. Garekar, M. L. Epstein, and T. L'Ecuyer Neonatal Supraventricular Tachycardia (SVT) NeoReviews, July 1, 2005; 6(7): e339 - e350. [Full Text] [PDF] |
||||
![]() |
T. P. Graham Jr The year in congenital heart disease J. Am. Coll. Cardiol., June 2, 2004; 43(11): 2132 - 2141. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |